# Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Source: https://onco.cc/trials/nct05555732/  
OnCo record `nct05555732` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Datopotamab deruxtecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.

## Summary

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). ClinicalTrials.gov record last updated 2026-06-23: active not recruiting. Enrollment is planned at 1170 participants. Primary completion is estimated at 2029-05-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin. Registered primary measures: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants; Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive; Overall Survival in All Randomized Participants.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Also known as: TROPION-Lung07
- Tags: ctgov-ingest
- Registry id: NCT05555732
- Phase: 3
- Setting: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- Sponsor: Daiichi Sankyo
- Enrolled: 1170

## Notes

- ClinicalTrials.gov record last updated 2026-06-23: active not recruiting. Enrollment is planned at 1170 participants. Primary completion is estimated at 2029-05-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT05555732: https://clinicaltrials.gov/study/NCT05555732

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct05555732.json